Format

Send to

Choose Destination
Am J Obstet Gynecol. 1996 May;174(5):1450-5.

Placental passage of angiotensin-converting enzyme inhibitors.

Author information

1
Department of Obstetrics and Gynecology, University of Vienna, Austria.

Abstract

OBJECTIVE:

Placental passage of the angiotensin-converting enzyme inhibitors temocapril and enalapril was investigated in a placental perfusion model.

STUDY DESIGN:

In an open system a placental lobe was perfused on both the maternal and the fetal side with a blood-free medium containing the test substances plus a reference substance on the maternal side. Six placentas were perfused with temocapril and five with enalapril. The drugs were measured by gas chromatography-mass spectrometry.

RESULTS:

Both angiotensin-converting enzyme inhibitors crossed the human placenta in the maternal-fetal direction in similar quantities. Temocapril showed the same pharmacokinetic characteristics as enalapril.

CONCLUSIONS:

This was the first study to quantify the placental transfer of angiotensin-converting enzyme inhibitors. These antihypertensive agents should not be taken during pregnancy, to avoid any potential hazards to the fetus.

PMID:
9065110
DOI:
10.1016/s0002-9378(96)70587-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center